MoneyAugust 29, 2026via TechCrunch AI
“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Why it matters
A major biotech VC is reshaping the funding game around AI-native biology startups, signaling a shift from the mega-fund model to focused, smaller bets — and revealing where capital thinks the leverage actually is in AI-driven drug discovery.
Key signals
- Vijay Pande left a16z biotech practice (~$4B AUM)
- Founded VZVC, positioned as AI-native and significantly smaller
- Moving from ~30 bets/year model to smaller number of concentrated bets
- Focus: open, shared datasets vs. proprietary/walled data for AI in medicine
- Biology framed as shifting from discovery science to engineering discipline
- Clinical trials remain cost barrier to AI drug development transformation
- Vijay Pande left a16z's ~$4B biotech practice
- Started VZVC as smaller, AI-native fund
- Shift from 30 bets/year model to smaller portfolio
- Thesis: biology moving from discovery to engineering via AI
- Open, shared datasets emphasized over proprietary approaches
- Clinical trial costs remain major constraint
The hook
$4B to boutique: Vijay Pande's bet-small thesis after leaving a16z biotech.
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared dat…